BioViva USA Inc. announced the issuance of U.S. Patent No. 12,653,907, titled Methods of Treating or Preventing Age-Related Disorders, covering therapeutic methods that combine human telomerase reverse transcriptase (hTERT) and Follistatin-344 (FST).
The patent was issued by the United States Patent and Trademark Office on June 16, 2026, and BioViva USA Inc. is the assignee.
The company claims the patent protects a dual-gene strategy targeting telomere maintenance, muscle biology and metabolic function, with issued claims addressing telomere length, muscle mass and blood-glucose levels.
The patent also encompasses genetic delivery approaches, including the use of viral vectors such as adeno-associated virus (AAV).
BioViva positions the grant as an addition to its intellectual-property portfolio focused on genetic approaches to age-related disorders and highlights research programs involving telomere maintenance, tissue regeneration, metabolic pathways and cognitive function.
The press release notes that patent issuance does not constitute regulatory approval and that the technologies remain investigational.
